EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance

Mohd Nazzary Mamat Yusof iD, Kah Teik Chew iD, Nirmala Chandralega Kampan iD, Mohamad Nasir Shafiee

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242015233 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Mohd Nazzary Mamat Yusof und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gynaecologic-Oncology Unit, Department of Obstetrics and Gynaecology, Hospital Canselor Tuanku Muhriz, Faculty of Medicine, Universiti Kebangsaan Mal…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Endometrial Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Grant Scheme by the Ministry of Higher Education Malaysia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The landscape of diagnosing and treating endometrial cancer is undergoing a profound transformation due to the integration of molecular analysis and innovative therapeutic approaches. For several decades, the cornerstone treatments for endometrial cancer have included surgical resection, cytotoxic chemotherapy, hormonal therapy, and radiation therapy. However, in recent years, the concept of personalised medicine has gained momentum, reshaping the way clinicians approach cancer treatment. Tailoring treatments based on specific biomarkers has evolved into a standard practice in both initial and recurrent therapy protocols. This review aims to provide an in-depth exploration of the current state of molecular analysis and treatment strategies in the context of endometrial cancer, focusing on the immunological aspect of the PD-1/PD-L1 axis. Furthermore, it seeks to shed light on emerging and innovative approaches that hold promise for the future modulation of endometrial cancer treatments. In essence, as researchers delve into the complex molecular landscape of endometrial cancer and harness the understanding of the PD-1/PD-L1 axis, we are paving the way for more targeted, effective, and personalised therapies that have the potential to significantly improve the outcomes and quality of life for patients with this challenging disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenEndometrial NeoplasmsFemaleHumansClinical RelevanceProgrammed Cell Death 1 ReceptorQuality of Life

Stichwörter der Autor:innen

PD-1PD-L1endometrial cancerimmune-checkpoint inhibitormolecular classificationnovel targeted therapy

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Gynaecologic-Oncology Unit, Department of Obstetrics and Gynaecology, Hospital Canselor Tuanku Muhriz, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.

ORCID-Profile: Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan

Förderung

  • Fundamental Research Grant Scheme by the Ministry of Higher Education Malaysia

Zitieren

APA

Mamat Yusof, M. N., Chew, K. T., Kampan, N. C., & Shafiee, M. N. (2023). Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015233

Vancouver

Mamat Yusof MN, Chew KT, Kampan NC, Shafiee MN. Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015233

BibTeX
@article{MamatYusof2023,
  author = {Mamat Yusof, Mohd Nazzary and Chew, Kah Teik and Kampan, Nirmala Chandralega and Shafiee, Mohamad Nasir},
  title = {Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242015233}
}
Kostenlos starten →